All News
46 articles in total
Eli Lilly's Inluriyo Approved: A New Treatment for ESR1-Mutated Advanced Breast Cancer
Eli Lilly and Company's oral drug Inluriyo (imlunestrant) has received approval from the U.S. Food and Drug Administration for the treatment of a specific type of advanced or metastatic breast cancer.
Palladium-Catalyzed C-S Coupling Breakthrough Enables Efficient Synthesis of JAK Inhibitor GDC-9918
A scientific research team has made a major breakthrough in the production process of the JAK1/2 inhibitor, GDC-9918. They have successfully resolved two key challenges in large-scale manufacturing, paving the way for the drug's industrialization.
Haisco's Major New Drug Approved for New Indication, Filling a Domestic Gap
Haisco pharmaceutical's innovative drug "Sishujing®" (Anrikefon Injection) has been approved for a new indication, which can be used for the treatment of moderate to severe pruritus in adult patients with chronic kidney disease (CKD) undergoing hemodialysis. This is China's first highly selective peripheral κ-opioid receptor agonist approved for this indication.
Rising Heat in Depression Treatment: A New Journey for Innovative Drug Development
Depression has become a major global public health challenge. In China, the lifetime prevalence reaches 6.8%, affecting over 95 million people. Huge unmet medical needs are driving increased investment in the industry, with pharmaceutical giants like Johnson & Johnson and AbbVie recently making significant acquisitions, highlighting their continued focus on this sector.
Sanofi's Rilzabrutinib Approval: World's First Autoimmune BTK Inhibitor Fills ITP Treatment Gap
On August 29, 2025, Sanofi announced that its BTK inhibitor rilzabrutinib (Wayrilz) was approved for marketing by the US FDA.
Aficamten's Phase III Success Will Change the Landscape of HCM Treatment
Cytokinetics announced positive results from the Phase III MAPLE-HCM trial of its drug aficamten for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).